Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Long-Term Debt Repayments: 2020-2024

Historic Long-Term Debt Repayments for SAB Biotherapeutics (SABS) over the last 5 years, with Dec 2024 value amounting to $1.3 million.

  • SAB Biotherapeutics' Long-Term Debt Repayments fell 100.00% to $3 in Q3 2025 from the same period last year, while for Sep 2025 it was $515,982, marking a year-over-year decrease of 60.52%. This contributed to the annual value of $1.3 million for FY2024, which is 25.50% up from last year.
  • As of FY2024, SAB Biotherapeutics' Long-Term Debt Repayments stood at $1.3 million, which was up 25.50% from $1.0 million recorded in FY2023.
  • Over the past 5 years, SAB Biotherapeutics' Long-Term Debt Repayments peaked at $2.3 million during FY2022, and registered a low of $32,506 during FY2020.
  • For the 3-year period, SAB Biotherapeutics' Long-Term Debt Repayments averaged around $1.5 million, with its median value being $1.3 million (2024).
  • Per our database at Business Quant, SAB Biotherapeutics' Long-Term Debt Repayments spiked by 3,262.61% in 2021 and then crashed by 54.49% in 2023.
  • Yearly analysis of 5 years shows SAB Biotherapeutics' Long-Term Debt Repayments stood at $32,506 in 2020, then spiked by 3,262.61% to $1.1 million in 2021, then soared by 106.78% to $2.3 million in 2022, then plummeted by 54.49% to $1.0 million in 2023, then grew by 25.50% to $1.3 million in 2024.